The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia

Luca Laurenti, Simona Sica, Dimitar G. Efremov

Risultato della ricerca: Contributo in rivistaArticolo in rivista

4 Citazioni (Scopus)

Abstract

Autoimmune cytopenias are a frequent complication in CLL, occurring in approximately 5-10% of the patients. The most common manifestation is autoimmune haemolytic anaemia, followed by immune thrombocytopenia and only rarely pure red blood cell aplasia or autoimmune granulocytopenia. Initial treatment is as for the idiopathic autoimmune cytopenias, with most patients responding to conventional corticosteroid therapy. Patients, who do not respond to conventional therapy after 4-6 weeks, should be considered for alternative immunosuppression, monoclonal antibody therapy or splenectomy. While randomized trials demonstrating the benefit of rituximab in CLL-related autoimmune diseases are still lacking, there are considerable data in the literature that provide evidence for its effectiveness. The monoclonal antibody alemtuzumab also displays considerable activity against both the malignant disease and the autoimmune complication in patients with CLL, although at the expense of greater toxicity. A number of new monoclonal antibodies, such as ofatumumab, GA-101, lumiliximab, TRU-016, epratuzumab, and galiximab, are currently investigated in CLL and their activity in CLL-related autoimmune cytopenias should be evaluated in future studies.
Lingua originaleEnglish
pagine (da-a)e2013027-e2013027
RivistaMediterranean Journal of Hematology and Infectious Diseases
Volume5
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • CLL

Fingerprint Entra nei temi di ricerca di 'The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia'. Insieme formano una fingerprint unica.

Cita questo